MOTS-C vs SS-31 vs NAD+: Research Comparison
MOTS-C, SS-31, and NAD+ are often grouped under mitochondrial, longevity, and cellular energy research. But they work through different research frameworks. MOTS-C is a mitochondrial-derived peptide. SS-31, also known as elamipretide, is a mitochondria-targeting peptide. NAD+ is a central cellular coenzyme involved in metabolism, energy production, and repair pathways.
Compound-by-compound briefing
| Field | MOTS-C | SS-31 | NAD+ |
|---|---|---|---|
| Commonly researched for | Mitochondrial signaling, metabolic stress response, insulin sensitivity, exercise biology, aging research, and energy regulation. | Mitochondrial dysfunction, cardiolipin biology, oxidative stress, rare mitochondrial disease, muscle function, and cellular energy research. | Cellular energy metabolism, redox biology, DNA repair pathways, sirtuin-related research, aging biology, fatigue, and metabolic health. |
| Mechanism of interest | A mitochondrial-derived peptide studied for AMPK-related metabolic stress signaling, nuclear gene expression effects, glucose metabolism, and exercise adaptation models. | Mitochondria-targeting peptide that binds cardiolipin in the inner mitochondrial membrane and is studied for mitochondrial structure, oxidative stress, and ATP production. | Essential coenzyme in redox reactions and a substrate for enzymes involved in cellular repair, metabolism, and stress response. |
| Evidence strength | Preclinical to Early | Moderate to Strong for specific disease research. Stronger than most research peptides because elamipretide has FDA approval for a rare condition. | Moderate for raising NAD-related biomarkers with precursors. Mixed for broad health outcome claims. |
| Human evidence | Limited. Human research interest is growing, but strong clinical evidence for direct MOTS-C intervention remains limited. | Clinical evidence exists in mitochondrial disease contexts. Elamipretide received FDA accelerated approval for Barth syndrome in patients meeting specific criteria. | Growing. Human studies suggest NAD+ precursors can raise NAD-related metabolites, but clinical benefits for anti-aging, performance, or disease prevention remain less certain. |
| Preclinical evidence | More developed. Animal and cell studies support interest in metabolic regulation, insulin sensitivity, exercise adaptation, and stress resistance. | Extensive mitochondrial and oxidative stress research across models. | Strong mechanistic and animal-model interest in metabolism, aging biology, and repair pathways. |
| Main caution | Not FDA-approved. FDA has flagged MOTS-C in compounding-risk context and noted lack of identified human exposure data for drug products containing MOTS-C. | FDA approval is specific to a rare disease context and should not be generalized to anti-aging, performance, or wellness claims. | NAD+ marketing often outruns the evidence. Raising a biomarker does not automatically prove meaningful clinical benefit. |
| Regulatory status | Not FDA-approved for general clinical use. | Elamipretide has FDA accelerated approval for Barth syndrome under specific criteria. General wellness, longevity, or performance uses are not FDA-approved. | NAD+ and NAD-related precursors exist in supplement and clinical-wellness contexts, but NAD+ infusion claims are not FDA-approved as anti-aging treatments. |
- Commonly researched for
- Mitochondrial signaling, metabolic stress response, insulin sensitivity, exercise biology, aging research, and energy regulation.
- Mechanism of interest
- A mitochondrial-derived peptide studied for AMPK-related metabolic stress signaling, nuclear gene expression effects, glucose metabolism, and exercise adaptation models.
- Evidence strength
- Preclinical to Early
- Human evidence
- Limited. Human research interest is growing, but strong clinical evidence for direct MOTS-C intervention remains limited.
- Preclinical evidence
- More developed. Animal and cell studies support interest in metabolic regulation, insulin sensitivity, exercise adaptation, and stress resistance.
- Main caution
- Not FDA-approved. FDA has flagged MOTS-C in compounding-risk context and noted lack of identified human exposure data for drug products containing MOTS-C.
- Regulatory status
- Not FDA-approved for general clinical use.
- Commonly researched for
- Mitochondrial dysfunction, cardiolipin biology, oxidative stress, rare mitochondrial disease, muscle function, and cellular energy research.
- Mechanism of interest
- Mitochondria-targeting peptide that binds cardiolipin in the inner mitochondrial membrane and is studied for mitochondrial structure, oxidative stress, and ATP production.
- Evidence strength
- Moderate to Strong for specific disease research. Stronger than most research peptides because elamipretide has FDA approval for a rare condition.
- Human evidence
- Clinical evidence exists in mitochondrial disease contexts. Elamipretide received FDA accelerated approval for Barth syndrome in patients meeting specific criteria.
- Preclinical evidence
- Extensive mitochondrial and oxidative stress research across models.
- Main caution
- FDA approval is specific to a rare disease context and should not be generalized to anti-aging, performance, or wellness claims.
- Regulatory status
- Elamipretide has FDA accelerated approval for Barth syndrome under specific criteria. General wellness, longevity, or performance uses are not FDA-approved.
- Commonly researched for
- Cellular energy metabolism, redox biology, DNA repair pathways, sirtuin-related research, aging biology, fatigue, and metabolic health.
- Mechanism of interest
- Essential coenzyme in redox reactions and a substrate for enzymes involved in cellular repair, metabolism, and stress response.
- Evidence strength
- Moderate for raising NAD-related biomarkers with precursors. Mixed for broad health outcome claims.
- Human evidence
- Growing. Human studies suggest NAD+ precursors can raise NAD-related metabolites, but clinical benefits for anti-aging, performance, or disease prevention remain less certain.
- Preclinical evidence
- Strong mechanistic and animal-model interest in metabolism, aging biology, and repair pathways.
- Main caution
- NAD+ marketing often outruns the evidence. Raising a biomarker does not automatically prove meaningful clinical benefit.
- Regulatory status
- NAD+ and NAD-related precursors exist in supplement and clinical-wellness contexts, but NAD+ infusion claims are not FDA-approved as anti-aging treatments.
Comparing Compounds? Read This First.
The Playbook helps you understand evidence quality, mechanism claims, safety limitations, and sourcing red flags before comparing research compounds.
Educational research only. No medical advice, dosing instructions, treatment recommendations, or personalized healthcare guidance.
Plain-language difference
MOTS-C is about mitochondrial signaling. SS-31 is about mitochondrial membrane and cardiolipin protection. NAD+ is about cellular energy chemistry and repair metabolism. They all sit near the mitochondria conversation, but they do not answer the same research question.
Mechanism comparison
MOTS-C is a signaling peptide connected to metabolic stress response and AMPK-related pathways. SS-31 targets mitochondria more directly through cardiolipin biology in the inner mitochondrial membrane. NAD+ is not a peptide; it is a coenzyme central to energy transfer, redox biology, and enzyme systems involved in repair and metabolism. The clean distinction is signal, structure, and coenzyme.
Evidence comparison
SS-31 has the strongest clinical footing because elamipretide has disease-specific FDA accelerated approval. NAD+ has broad human supplement research, especially around NAD+ precursors, but benefits beyond biomarker changes remain mixed. MOTS-C is promising but earlier, with stronger preclinical than direct human intervention evidence.
Safety and regulatory context
Do not present mitochondrial compounds as proven anti-aging interventions. SS-31 approval does not validate general longevity use. NAD+ enthusiasm should be separated from clinical proof. MOTS-C remains investigational and not FDA-approved. The mitochondrial category attracts hype, so this page must stay disciplined.
Continue down a research path
Full compound breakdowns
Research-Use-Only Sourcing Standards
Before evaluating any supplier, review the standards that matter: Certificate of Analysis access, batch transparency, purity testing, clear labeling, restrained claims, and research-use-only positioning.
- 01Certificate of Analysis available
- 02Batch or lot transparency
- 03Purity testing clearly stated
- 04Clear compound labeling
- 05No exaggerated medical claims
- 06Research-use-only language
- 07Supplier disclosure visible
Some supplier links may be affiliate links. Peptide Pressure may earn compensation. Affiliate relationships do not influence evidence grading, safety framing, or editorial standards.
Disclaimer: This page is for educational and research purposes only. It does not provide medical advice, dosing instructions, treatment recommendations, or personalized healthcare guidance.